Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Grover Miller to Humans

This is a "connection" page, showing publications Grover Miller has written about Humans.

 
Connection Strength
  
 
 
0.760
  
  1. Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
    View in: PubMed
    Score: 0.031
  2. Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology. 2021 06 30; 458:152832.
    View in: PubMed
    Score: 0.030
  3. Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. Drug Metab Dispos. 2021 02; 49(2):133-141.
    View in: PubMed
    Score: 0.029
  4. Barnette DA, Schleiff MA, Osborn LR, Flynn N, Matlock M, Swamidass SJ, Miller GP. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology. 2020 07; 440:152478.
    View in: PubMed
    Score: 0.028
  5. Barnette DA, Davis MA, Flynn N, Pidugu AS, Swamidass SJ, Miller GP. Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. Biochem Pharmacol. 2019 12; 170:113661.
    View in: PubMed
    Score: 0.027
  6. Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP. CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. Chem Res Toxicol. 2019 06 17; 32(6):1151-1164.
    View in: PubMed
    Score: 0.026
  7. Pouncey DL, Hartman JH, Moore PC, Dillinger DJ, Dickerson KW, Sappington DR, Smith ES, Boysen G, Miller GP. Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagul Fibrinolysis. 2018 Nov; 29(7):602-612.
    View in: PubMed
    Score: 0.025
  8. Barnette DA, Davis MA, Dang NL, Pidugu AS, Hughes T, Swamidass SJ, Boysen G, Miller GP. Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches. Biochem Pharmacol. 2018 10; 156:10-21.
    View in: PubMed
    Score: 0.024
  9. Kim SY, Jones DR, Kang JY, Yun CH, Miller GP. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Xenobiotica. 2019 Apr; 49(4):397-403.
    View in: PubMed
    Score: 0.024
  10. Barnette DA, Johnson BP, Pouncey DL, Nshimiyimana R, Desrochers LP, Goodwin TE, Miller GP. Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases. Drug Metab Dispos. 2017 09; 45(9):1000-1007.
    View in: PubMed
    Score: 0.023
  11. Hartman JH, Letzig LG, Roberts DW, James LP, Fifer EK, Miller GP. Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. Biochem Pharmacol. 2015 Oct 01; 97(3):341-9.
    View in: PubMed
    Score: 0.020
  12. Hartman JH, Knott K, Miller GP. CYP2E1 hydroxylation of aniline involves negative cooperativity. Biochem Pharmacol. 2014 Feb 01; 87(3):523-33.
    View in: PubMed
    Score: 0.018
  13. Hartman JH, Boysen G, Miller GP. Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica. 2013 Sep; 43(9):755-64.
    View in: PubMed
    Score: 0.017
  14. Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 01; 6(3):157-64.
    View in: PubMed
    Score: 0.016
  15. Hartman JH, Boysen G, Miller GP. CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos. 2012 Oct; 40(10):1976-83.
    View in: PubMed
    Score: 0.016
  16. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  17. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  18. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  19. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  20. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  21. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  22. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  23. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  24. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  25. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.015
  26. Jones DR, Boysen G, Miller GP. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 01; 879(15-16):1056-62.
    View in: PubMed
    Score: 0.015
  27. Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec; 4(4):213-9.
    View in: PubMed
    Score: 0.014
  28. Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010 Feb; 42(1):55-61.
    View in: PubMed
    Score: 0.014
  29. Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul; 22(7):1239-45.
    View in: PubMed
    Score: 0.013
  30. Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos. 2008 Nov; 36(11):2211-8.
    View in: PubMed
    Score: 0.012
  31. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  32. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  33. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  34. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  35. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  36. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  37. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  38. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  39. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  40. Collom SL, Laddusaw RM, Burch AM, Kuzmic P, Perry MD, Miller GP. CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem. 2008 Feb 08; 283(6):3487-3496.
    View in: PubMed
    Score: 0.012
  41. Wang S, Argikar UA, Chatzopoulou M, Cho S, Crouch RD, Dhaware D, Gu TJ, Heck CJS, Johnson KM, Kalgutkar AS, Liu J, Ma B, Miller GP, Rowley JA, Seneviratne HK, Zhang D, Khojasteh SC. Bioactivation and reactivity research advances - 2023 year in review. Drug Metab Rev. 2024 Aug; 56(3):247-284.
    View in: PubMed
    Score: 0.009
  42. Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck CJS, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC. Bioactivation and reactivity research advances - 2021 year in review. Drug Metab Rev. 2022 08; 54(3):246-281.
    View in: PubMed
    Score: 0.008
  43. Datta A, Flynn NR, Barnette DA, Woeltje KF, Miller GP, Swamidass SJ. Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. PLoS Comput Biol. 2021 07; 17(7):e1009053.
    View in: PubMed
    Score: 0.007
  44. Khojasteh SC, Argikar UA, Driscoll JP, Heck CJS, King L, Jackson KD, Jian W, Kalgutkar AS, Miller GP, Kramlinger V, Rietjens IMCM, Teitelbaum AM, Wang K, Wei C. Novel advances in biotransformation and bioactivation research - 2020 year in review. Drug Metab Rev. 2021 08; 53(3):384-433.
    View in: PubMed
    Score: 0.007
  45. Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metab Rev. 2020 08; 52(3):333-365.
    View in: PubMed
    Score: 0.007
  46. Matlock MK, Tambe A, Elliott-Higgins J, Hines RN, Miller GP, Swamidass SJ. A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. Chem Res Toxicol. 2019 08 19; 32(8):1707-1721.
    View in: PubMed
    Score: 0.007
  47. Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev. 2018 08; 50(3):221-255.
    View in: PubMed
    Score: 0.006
  48. Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. Chem Res Toxicol. 2018 02 19; 31(2):68-80.
    View in: PubMed
    Score: 0.006
  49. Bostian AC, Maddukuri L, Reed MR, Savenka T, Hartman JH, Davis L, Pouncey DL, Miller GP, Eoff RL. Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19; 29(1):101-8.
    View in: PubMed
    Score: 0.005
  50. Freyaldenhoven S, Li Y, Kocabas AM, Ziu E, Ucer S, Ramanagoudr-Bhojappa R, Miller GP, Kilic F. The role of ERp44 in maturation of serotonin transporter protein. J Biol Chem. 2012 May 18; 287(21):17801-17811.
    View in: PubMed
    Score: 0.004
  51. Xiong Y, Patana AS, Miley MJ, Zielinska AK, Bratton SM, Miller GP, Goldman A, Finel M, Redinbo MR, Radominska-Pandya A. The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis. Drug Metab Dispos. 2008 Mar; 36(3):517-22.
    View in: PubMed
    Score: 0.003
  52. Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2008 Jan; 324(1):139-48.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.